Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population-based analysis

Cancer

Volumn 120, Issue 13, 2014, Pages 2039-2049

  Shen, Chan ^a   Shih, Ya Chen Tina ^b   Xu, Ying ^a   Yao, James C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

and End Results (SEER) Medicare; Epidemiology; health services for the aged; malignant carcinoid syndrome; neuroendocrine tumors; octreotide; somatostatin analog; Surveillance

Indexed keywords

OCTREOTIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SOMATOSTATIN DERIVATIVE;

AGE DISTRIBUTION; AGED; AGING; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CARCINOID SYNDROME; CONTROLLED STUDY; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESIDENTIAL AREA; SEX RATIO; SURVIVAL TIME; VERY ELDERLY; AND END RESULTS (SEER)-MEDICARE; CANCER GRADING; CANCER REGISTRY; COMORBIDITY; DRUG ADMINISTRATION; ELDERLY CARE; EPIDEMIOLOGY; ETHNOLOGY; KAPLAN MEIER METHOD; MEDICARE; MORTALITY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVEILLANCE; TREATMENT OUTCOME; UNITED STATES; VIPOMA;

AND END RESULTS (SEER)-MEDICARE; EPIDEMIOLOGY; HEALTH SERVICES FOR THE AGED; MALIGNANT CARCINOID SYNDROME; NEUROENDOCRINE TUMORS; OCTREOTIDE; SOMATOSTATIN ANALOG; SURVEILLANCE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MALIGNANT CARCINOID SYNDROME; MEDICARE; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES; VIPOMA;

EID: 84902551504     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28653     Document Type: Article

References (23)

1. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E,. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008; 100: 1282-1289.
2. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331: 1199-1203.
3. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514-523.
4. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-513.
5. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26: 3063-3072.
6. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999; 17: 600-606.
7. Rinke A, Muller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27: 4656-4663.
8. Clark OH, Benson AB, 3rd, Berlin JD, et al. NCCN Neuroendocrine Tumors Panel Members. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009; 7: 712-747.
9. Oberg K, Akerstrom G, Rindi G, Jelic S, ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v223-v227.
10. Eriksson B, Kloppel G, Krenning E, et al. Frascati Consensus Conference participants. Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008; 87: 8-19.
11. Boudreaux JP, Klimstra DS, Hassan MM, et al. North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010; 39: 753-766.
12. National Cancer Institute. Surveillance, Epidemiology and End Results Program. seer.cancer.gov/. Accessed March 3, 2014.
13. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (suppl 8): IV-3-IV-18.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
15. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
16. Romano PS, Roos LL, Jollis JG,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 1075-1079; discussion 1081-1090.
17. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
18. Bird CE, Shugarman LR, Lynn J,. Age and gender differences in health care utilization and spending for Medicare beneficiaries in their last years of life. J Palliat Med. 2002; 5: 705-712.
19. Chou AF, Scholle SH, Weisman CS, Bierman AS, Correa-de-Araujo R, Mosca L,. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues. 2007; 17: 120-130.
20. Garg PP, Furth SL, Fivush BA, Powe NR,. Impact of gender on access to the renal transplant waiting list for pediatric and adult patients. J Am Soc Nephrol. 2000; 11: 958-964.
21. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC,. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002; 20: 1786-1792.
22. IPSEN Innovation for Patient Care. Detailed Results of the Phase III CLARINET Study at the European Cancer Congress 2013 on 28 September 2013. ipsen.com/wp-content/uploads/2013/09/PR-Dates-Late-breaking-news-and-Press- conference-Clarinet-EN.pdf. Accessed March 3, 2014.
23. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2010). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences Surveillance Research Program, Surveillance Systems Branch; 2013, based on the November 2012 submission.